Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug Post published:February 18, 2021 Post category:Press Release
Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board Post published:February 11, 2021 Post category:Press Release
Nova Mentis Psilocybin Approved for Shipment to Italy Post published:February 9, 2021 Post category:Press Release
Nova Launches Preclinical Autism Spectrum Disorder Therapeutic Study Post published:January 26, 2021 Post category:Press Release
Nova Mentis Appoints Dr. Julia V. Perederiy, PhD to Scientific Advisory Board Post published:January 13, 2021 Post category:Press Release
Nova Mentis Appoints Dr. Kyle Ambert to Scientific Advisory Board Post published:January 4, 2021 Post category:Press Release
Nova Mentis Expands Psychedelic Drug Pipeline Post published:December 29, 2020 Post category:Press Release
Nova Mentis Uncovers Diagnostic Biomarkers in Preclinical Autism Study Post published:December 8, 2020 Post category:Press Release
Nova Mentis Appoints Dr. Marvin S. Hausman as Chairman of Scientific Advisory Board Post published:December 3, 2020 Post category:Press Release
Nova Mentis Life Science Completes Acquisition of Pilz Bioscience Post published:November 30, 2020 Post category:Press Release